Abiopharma

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Oculis birtir boð á aðalfund

Oculis Publishes Invitation to the Annual General Meeting

Stevanato Group to Participate in Upcoming Investor Conferences

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE